|
May 30
|
Pfizer Reports Survival Gains In Colorectal Cancer Study, Combo Therapy Cuts Death Risk By Over 50%
|
|
May 30
|
ASCO25: Pfizer’s Braftovi combo boasts 47% drop in disease progression in mCRC
|
|
May 30
|
Pfizer’s BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
|
|
May 30
|
Pfizer Inc. (PFE) Ends Acepodia Partnership Amid Depo-Provera Legal Woes
|
|
May 29
|
Pfizer (NYSE:PFE) Ends Collaboration With Acepodia And Faces Depo-Provera Legal Challenges
|
|
May 29
|
PFE or LLY: Which Is the Better Value Stock Right Now?
|
|
May 29
|
Pfizer (PFE) Down 5% Since Last Earnings Report: Can It Rebound?
|
|
May 29
|
Pfizer and Arvinas gamble to shift breast cancer treatment paradigm
|
|
May 29
|
Are Investors Undervaluing Pfizer (PFE) Right Now?
|
|
May 29
|
5 Valuable Price-to-Book Stocks to Strengthen Your Portfolio
|
|
May 28
|
With 67% ownership of the shares, Pfizer Inc. (NYSE:PFE) is heavily dominated by institutional owners
|
|
May 27
|
Is Pfizer Stock a Buy After This $1.25 Billion Investment?
|
|
May 27
|
Pfizer headquarters conversion project in Manhattan gets $720m loan
|
|
May 26
|
Roche Gets CHMP Nod for Itovebi Combo in the EU for Breast Cancer
|
|
May 24
|
Junkiest Junk Is Offering a Warning Sign for Debt
|
|
May 24
|
Pfizer Inc. (PFE) Delivers Oncology Milestones with MesoC2 Debut and XTANDI Survival Boost
|
|
May 24
|
Down 63%, Should You Buy the Dip on Pfizer?
|
|
May 24
|
Charting the Global Economy: Long-Term Bond Yields Soar Around the World
|
|
May 24
|
1 Ultra-High-Yield Dividend Stock Down 57% to Buy Hand Over Fist
|
|
Mar 14
|
Pfizer (NYSE:PFE) Faces Shareholder Proposals on Religious Discrimination and Executive Pay Limits
|